GERON CORP (GERN) Fundamental Analysis & Valuation

NASDAQ:GERN • US3741631036

Current stock price

1.54 USD
+0.03 (+1.99%)
At close:
1.59 USD
+0.05 (+3.25%)
Pre-Market:

This GERN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. GERN Profitability Analysis

1.1 Basic Checks

  • GERN had negative earnings in the past year.
  • In the past year GERN has reported a negative cash flow from operations.
  • GERN had negative earnings in each of the past 5 years.
  • In the past 5 years GERN always reported negative operating cash flow.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -14.64%, GERN is in the better half of the industry, outperforming 78.25% of the companies in the same industry.
  • GERN has a Return On Equity of -36.97%. This is in the better half of the industry: GERN outperforms 69.13% of its industry peers.
Industry RankSector Rank
ROA -14.64%
ROE -36.97%
ROIC N/A
ROA(3y)-30.25%
ROA(5y)-43.32%
ROE(3y)-57.83%
ROE(5y)-88.55%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 97.42%, GERN belongs to the best of the industry, outperforming 96.89% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for GERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. GERN Health Analysis

2.1 Basic Checks

  • GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GERN has more shares outstanding than it did 1 year ago.
  • GERN has more shares outstanding than it did 5 years ago.
  • GERN has a worse debt/assets ratio than last year.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • GERN has an Altman-Z score of -1.95. This is a bad value and indicates that GERN is not financially healthy and even has some risk of bankruptcy.
  • GERN has a Altman-Z score (-1.95) which is in line with its industry peers.
  • GERN has a Debt/Equity ratio of 1.03. This is a high value indicating a heavy dependency on external financing.
  • GERN has a Debt to Equity ratio of 1.03. This is in the lower half of the industry: GERN underperforms 76.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z -1.95
ROIC/WACCN/A
WACC9.2%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

2.3 Liquidity

  • A Current Ratio of 4.66 indicates that GERN has no problem at all paying its short term obligations.
  • GERN has a Current ratio (4.66) which is in line with its industry peers.
  • A Quick Ratio of 3.62 indicates that GERN has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.62, GERN perfoms like the industry average, outperforming 46.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.62
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. GERN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 62.96% over the past year.
  • Looking at the last year, GERN shows a very strong growth in Revenue. The Revenue has grown by 138.83%.
  • Measured over the past years, GERN shows a very strong growth in Revenue. The Revenue has been growing by 274.39% on average per year.
EPS 1Y (TTM)62.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)138.83%
Revenue growth 3Y574.21%
Revenue growth 5Y274.39%
Sales Q2Q%1%

3.2 Future

  • The Earnings Per Share is expected to grow by 51.25% on average over the next years. This is a very strong growth
  • GERN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.44% yearly.
EPS Next Y55.8%
EPS Next 2Y50.17%
EPS Next 3Y35.9%
EPS Next 5Y51.25%
Revenue Next Year22.81%
Revenue Next 2Y32.87%
Revenue Next 3Y36.84%
Revenue Next 5Y37.44%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4

More info and screens

Find the best growth stocksShow best growing peers

1

4. GERN Valuation Analysis

4.1 Price/Earnings Ratio

  • GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

  • GERN's earnings are expected to grow with 35.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.17%
EPS Next 3Y35.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GERN Dividend Analysis

5.1 Amount

  • No dividends for GERN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GERN Fundamentals: All Metrics, Ratios and Statistics

GERON CORP

NASDAQ:GERN (4/30/2026, 8:00:02 PM)

Premarket: 1.59 +0.05 (+3.25%)

1.54

+0.03 (+1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners77.31%
Inst Owner Change0.01%
Ins Owners0.07%
Ins Owner Change3.82%
Market Cap986.99M
Revenue(TTM)183.88M
Net Income(TTM)-83.50M
Analysts78.46
Price Target3.32 (115.58%)
Short Float %12.93%
Short Ratio4.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.48%
Min EPS beat(2)10.87%
Max EPS beat(2)38.09%
EPS beat(4)4
Avg EPS beat(4)26.76%
Min EPS beat(4)10.87%
Max EPS beat(4)38.09%
EPS beat(8)8
Avg EPS beat(8)23.65%
EPS beat(12)11
Avg EPS beat(12)20.91%
EPS beat(16)14
Avg EPS beat(16)19.35%
Revenue beat(2)0
Avg Revenue beat(2)-9.54%
Min Revenue beat(2)-12.44%
Max Revenue beat(2)-6.64%
Revenue beat(4)1
Avg Revenue beat(4)-8.99%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)2.61%
Revenue beat(8)5
Avg Revenue beat(8)166.58%
Revenue beat(12)6
Avg Revenue beat(12)108.96%
Revenue beat(16)8
Avg Revenue beat(16)92.63%
PT rev (1m)2.63%
PT rev (3m)-2.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.68%
EPS NY rev (1m)0%
EPS NY rev (3m)3.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.37
P/FCF N/A
P/OCF N/A
P/B 4.37
P/tB 4.37
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.29
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -14.64%
ROE -36.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.42%
FCFM N/A
ROA(3y)-30.25%
ROA(5y)-43.32%
ROE(3y)-57.83%
ROE(5y)-88.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.34%
Cap/Sales 0.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.66
Quick Ratio 3.62
Altman-Z -1.95
F-Score2
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)107.55%
Cap/Depr(5y)113.28%
Cap/Sales(3y)117.04%
Cap/Sales(5y)87.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y55.8%
EPS Next 2Y50.17%
EPS Next 3Y35.9%
EPS Next 5Y51.25%
Revenue 1Y (TTM)138.83%
Revenue growth 3Y574.21%
Revenue growth 5Y274.39%
Sales Q2Q%1%
Revenue Next Year22.81%
Revenue Next 2Y32.87%
Revenue Next 3Y36.84%
Revenue Next 5Y37.44%
EBIT growth 1Y70.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.55%
EBIT Next 3Y19.92%
EBIT Next 5YN/A
FCF growth 1Y49.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.21%
OCF growth 3YN/A
OCF growth 5YN/A

GERON CORP / GERN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GERON CORP?

ChartMill assigns a fundamental rating of 3 / 10 to GERN.


Can you provide the valuation status for GERON CORP?

ChartMill assigns a valuation rating of 1 / 10 to GERON CORP (GERN). This can be considered as Overvalued.


What is the profitability of GERN stock?

GERON CORP (GERN) has a profitability rating of 2 / 10.


Can you provide the financial health for GERN stock?

The financial health rating of GERON CORP (GERN) is 3 / 10.